Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Antisense Oligonucleotides Market Outlook

The global antisense oligonucleotides market is projected to amass revenue of around US$ 5,519.6 million by 2033, up from US$ 2,913.5 million in 2023 moving forward with a CAGR of 6.6% during the forecast period.

The antisense oligonucleotides adoption trends are significantly swayed by their promising treatment options for a range of medical disorders. Moreover, they also facilitate the development of therapeutics affecting protein targets that cannot be treated with protein therapeutics, propelling the market growth. They target a particular malfunctioning gene, interfere with RNA function at the cellular level, and also be silenced or modulated and the same is catching the attention of market players.

The rising demand for antisense oligonucleotides is attributed to its aid in modifying the immune system that facilitates the treatment of a wide range of autoimmune disorders - that cannot be treated with available drugs.

It is easy to scale up the commercial scale GMP production of these oligonucleotides compared to other biologic therapies, spurring the adoption of antisense oligonucleotides.

Moreover, the market is enhanced by the minimal side effects of antisense oligonucleotides, which are controlled with ease as compared to other classes of drugs.

The antisense oligonucleotides sector has witnessed four FDA approvals [fomivirsen (Vitravene) approved in 1998 - which was discontinued due to low demand; pegaptanib (Macugen) in 2004; mipomersen (Kynamro) in 2013; and eteplirsen (Exondys 51) in 2016).

However, this market is yet to achieve recognition as a valuable drug category like biologics, small molecules, and gene and cell therapy.

However, this was projected to change with the approval of nusinersen (Spinraza) for treating spinal muscular atrophy (SMA), which is one of the most common genetic causes of infant mortality with no approved treatments.

Even when the market performance of antisense oligonucleotides is not predictable as like other segments of the industry, the market outlook is positively influenced by the leading players in the market and the amount of research and development investments.

Attributes Details
Antisense Oligonucleotides Market CAGR (2023 to 2033) 6.6%
Antisense Oligonucleotides Market Size (2023) US$ 2,913.5 million
Antisense Oligonucleotides Market Size (2033) US$ 5,519.6 million

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

What Factors are Shaping the Antisense Oligonucleotides Industry?

A strong pipeline of antisense oligonucleotides and increased focus on a large number of product approvals and commercialization are likely to expand the global antisense oligonucleotides sector size.

Moreover, significant advances in the field of antisense oligonucleotides at a therapeutic or clinical level are further contributing to the growth of the global market.

However, the global antisense oligonucleotides business is grappling with numerous challenges related to the diversity of oligonucleotides, delivery, and regulatory complexity.

Despite several advancements at clinical levels, the delivery of active oligonucleotides to the actual site within target cells is still one of the key challenges hindering the growth of the global antisense oligonucleotides sector. In addition to this, developing a new set of unique regulatory guidelines is also expected to hamper the market statistics.

Comparative View of the Market

Antisense Oligonucleotides Market:

Attributes Antisense Oligonucleotides Market
CAGR (2023 to 2033) 6.6%
Market Value (2033) US$ 5,519.6 million
Growth Factor Promising treatment offers for medical disorders
Opportunity Rising number of FDA approval
Trends Advanced pharmacological techniques

Oligonucleotides Market:

Attributes Oligonucleotides Market
CAGR (2023 to 2033) 5.3%
Market Value (2033) US$ 11,930 million
Growth Factor Widespread use in various ailments
Opportunity Technology advancement in pharmaceutical
Trends Rising demand for personalized treatment

Fructo-oligosaccharides Market:

Attributes Fructo-oligosaccharides Market
CAGR (2023 to 2033) 6%
Market Value (2033) US$ 4,919.5 million
Growth Factor Surging awareness about health awareness
Opportunity Growing research work to maintain digestive system
Trends Need for nutritional food additives
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Regional Analysis

Countries Market Share (2022)
United States 58%
Germany 3.3%
Japan 2.9%

Why is North America Expected to Dominate the Antisense Oligonucleotides Industry?

North America clearly dominates the global antisense oligonucleotides industry due to a strong product pipeline and an increasing number of FDA approvals in the region, contributing to the region’s market share of 60.9% in 2022.

For instance, the international biotechnology company Biogen Inc.'s Nusinersen, sold as Spinraza, received FDA approval in the USA in 2018. Health infrastructures and an increase in the use of oligonucleotides in the development of innovative pharmacological therapies are additional factors driving market expansion.

What are the Growth Prospects for the Europe Antisense Oligonucleotides Business?

In 2022, the Europe antisense oligonucleotides sector captured a share of 14.3%. In order to improve their product portfolio for antisense oligonucleotides, key players in Europe are concentrating on strategic mergers and acquisitions, in turn spurring the market growth in Europe.

For instance, in 2014, the multinational pharmaceutical and biopharmaceutical company AstraZeneca Plc. merged with the pharmaceutical firm Ionis Pharmaceuticals. Additionally, it is anticipated that a strong pipeline of important companies aids the market growth to some level.

How is the Start-up Ecosystem in the Antisense Oligonucleotides Industry?

While many organizations are working on RNA-based treatments and vaccines, including well-known companies like Pfizer, BioNtech, Moderna, etc., a few biotech start-ups are also emerging, shaping the market trends.

Examples:

  • RNA-targeting biopharmaceuticals are being created by the USA-based start-up Arrakis Therapeutics.

The company's tiny molecule medications bind to targets that were previously believed to be unreachable as well as those that were confirmed using genetic and pharmacological techniques.

These medications use multiple ways to either decrease RNA translation or splicing. Drugs for oncology, dyslipidemia, and uncommon disorders are in the startup's development.

  • Antisense RNA therapies are created by the Spanish start-up ARTHEx Biotech for hereditary illnesses.

The company's top therapeutic candidate for type 1 myotonic dystrophy is an anti-microRNA (DM1). The start-up's anti-miRs are shown to suppress microRNAs that repress MBNL1/2 genes in DM1 in muscle biopsies of patients.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

How Strong Is the Competition in the Antisense Oligonucleotides Business?

The market for antisense oligonucleotides is fairly consolidated, with a few competitors gaining a significant growing share. The market participants for antisense oligonucleotides are heavily invested in research and development. These activities assist the participants in developing novel formulations that are advantageous to the user.

A couple of recent developments are:

  • AmpTec, a renowned German company that specializes in mRNA contract development and manufacture, was purchased by MilliporeSigma (USA) (CDMO).

The agreement improves MilliporeSigma's capacity to produce and develop mRNA for its clients' usage in Covid-19 and numerous other diseases-related vaccines, therapies, and diagnostics.

  • oPools- oligo pools, a collection of 350-nucleotide-long, high-quality DNA oligonucleotides, was introduced by Integrated DNA Technology (USA).

Key player

  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics
  • Biogen
  • Alnylam Pharmaceuticals, Inc.
  • Antisense Therapeutics Limited
  • Isarna Therapeutics GmbH
  • Arrowhead Pharmaceuticals, Inc.
  • Atlantic Pharmaceuticals, Inc.
  • Enzon Pharmaceuticals, Inc.
  • Bio-Path Holdings, Inc.
  • Gene Signal International SA
  • GlaxoSmithKline plc
  • Geron Corporation
  • Grades
  • ICO Therapeutics
  • Aptose Biosciences
  • Marina Biotech
  • miRagen Therapeutics, Inc.
  • Synlogic, Inc.
  • OncoGenex Pharmaceuticals Inc.
  • Pharmaxis Ltd, Regulus Therapeutics Inc.
  • Rexahn Pharmaceuticals, Inc.
  • RXi Pharmaceuticals

Key Segments

By Drug:

  • Approved Drugs
  • Pegaptanib
  • Mipomersen
  • Eteplirsen
  • Pipeline Analysis

By Indication:

  • Ocular Diseases
  • Cancer
  • Diabetes
  • Amyotrophic Lateral Sclerosis (ALS)
  • Duchenne Muscular Dystrophy
  • Spinal Muscular Atrophy
  • Others

By Application:

  • Basic Research
  • Genomics
  • Target Validation
  • Drug Discovery

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • The Middle East and Africa
  • Europe

Frequently Asked Questions

Why is North America Emerging as an Opportunistic Market?

Robust product pipeline and rising FDA approvals in the region dominate the market.

What is the Lucrative Opportunity in the Market?

The rising number of FDA approvals is the key opportunity in the market.

What is the Key Trend of the Market?

Advanced pharmacological techniques are the key trend.

What Drives Sales of the Market?

Promising treatment offers for medical disorders.

What is the Growth Forecast for the Market?

The market is forecast to register a CAGR of 6.6% through 2033.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug, 2023 to 2033

        5.3.1. Approved Drugs

        5.3.2. Pegaptanib

        5.3.3. Mipomersen

        5.3.4. Eteplirsen

        5.3.5. Pipeline Analysis

    5.4. Y-o-Y Growth Trend Analysis By Drug, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

        6.3.1. Ocular Diseases

        6.3.2. Cancer

        6.3.3. Diabetes

        6.3.4. Amyotrophic Lateral Sclerosis (ALS)

        6.3.5. Duchenne Muscular Dystrophy

        6.3.6. Spinal Muscular Atrophy

        6.3.7. Others

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Application , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application , 2023 to 2033

        7.3.1. Basic Research

        7.3.2. Genomics

        7.3.3. Target Validation

        7.3.4. Drug Discovery

    7.4. Y-o-Y Growth Trend Analysis By Application , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Application , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA.

            9.2.1.2. Canada

        9.2.2. By Drug

        9.2.3. By Indication

        9.2.4. By Application

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug

        9.3.3. By Indication

        9.3.4. By Application

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug

        10.2.3. By Indication

        10.2.4. By Application

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug

        10.3.3. By Indication

        10.3.4. By Application

    10.4. Key Takeaways

11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Drug

        11.2.3. By Indication

        11.2.4. By Application

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug

        11.3.3. By Indication

        11.3.4. By Application

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Drug

        12.2.3. By Indication

        12.2.4. By Application

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug

        12.3.3. By Indication

        12.3.4. By Application

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Drug

        13.2.3. By Indication

        13.2.4. By Application

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug

        13.3.3. By Indication

        13.3.4. By Application

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Drug

        14.2.3. By Indication

        14.2.4. By Application

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug

        14.3.3. By Indication

        14.3.4. By Application

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Drug

        15.2.3. By Indication

        15.2.4. By Application

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug

        15.3.3. By Indication

        15.3.4. By Application

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA.

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug

            16.1.2.2. By Indication

            16.1.2.3. By Application

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug

            16.2.2.2. By Indication

            16.2.2.3. By Application

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug

            16.3.2.2. By Indication

            16.3.2.3. By Application

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug

            16.4.2.2. By Indication

            16.4.2.3. By Application

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug

            16.5.2.2. By Indication

            16.5.2.3. By Application

    16.6. United Kingdom.

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug

            16.6.2.2. By Indication

            16.6.2.3. By Application

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug

            16.7.2.2. By Indication

            16.7.2.3. By Application

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug

            16.8.2.2. By Indication

            16.8.2.3. By Application

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug

            16.9.2.2. By Indication

            16.9.2.3. By Application

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug

            16.10.2.2. By Indication

            16.10.2.3. By Application

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug

            16.11.2.2. By Indication

            16.11.2.3. By Application

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug

            16.12.2.2. By Indication

            16.12.2.3. By Application

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug

            16.13.2.2. By Indication

            16.13.2.3. By Application

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug

            16.14.2.2. By Indication

            16.14.2.3. By Application

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug

            16.15.2.2. By Indication

            16.15.2.3. By Application

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug

            16.16.2.2. By Indication

            16.16.2.3. By Application

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug

            16.17.2.2. By Indication

            16.17.2.3. By Application

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug

            16.18.2.2. By Indication

            16.18.2.3. By Application

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug

            16.19.2.2. By Indication

            16.19.2.3. By Application

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug

            16.20.2.2. By Indication

            16.20.2.3. By Application

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug

            16.21.2.2. By Indication

            16.21.2.3. By Application

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2022

            16.22.2.1. By Drug

            16.22.2.2. By Indication

            16.22.2.3. By Application

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2022

            16.23.2.1. By Drug

            16.23.2.2. By Indication

            16.23.2.3. By Application

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug

        17.3.3. By Indication

        17.3.4. By Application

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Ionis Pharmaceuticals, Inc.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Sarepta Therapeutics

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Biogen

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Alnylam Pharmaceuticals, Inc.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Antisense Therapeutics Limited

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Isarna Therapeutics GmbH

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Arrowhead Pharmaceuticals, Inc.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Alantic Pharmaceuticals, Inc.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Enzon Pharmaceuticals, Inc.

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Bio-Path Holdings, Inc.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

        18.1.11. Gene Signal International SA

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

        18.1.12. GlaxoSmithKline plc

            18.1.12.1. Overview

            18.1.12.2. Product Portfolio

            18.1.12.3. Profitability by Market Segments

            18.1.12.4. Sales Footprint

            18.1.12.5. Strategy Overview

                18.1.12.5.1. Marketing Strategy

        18.1.13. Geron Corporation

            18.1.13.1. Overview

            18.1.13.2. Product Portfolio

            18.1.13.3. Profitability by Market Segments

            18.1.13.4. Sales Footprint

            18.1.13.5. Strategy Overview

                18.1.13.5.1. Marketing Strategy

        18.1.14. Grades

            18.1.14.1. Overview

            18.1.14.2. Product Portfolio

            18.1.14.3. Profitability by Market Segments

            18.1.14.4. Sales Footprint

            18.1.14.5. Strategy Overview

                18.1.14.5.1. Marketing Strategy

        18.1.15. ICO Therapeutics

            18.1.15.1. Overview

            18.1.15.2. Product Portfolio

            18.1.15.3. Profitability by Market Segments

            18.1.15.4. Sales Footprint

            18.1.15.5. Strategy Overview

                18.1.15.5.1. Marketing Strategy

        18.1.16. Aptose Biosciences

            18.1.16.1. Overview

            18.1.16.2. Product Portfolio

            18.1.16.3. Profitability by Market Segments

            18.1.16.4. Sales Footprint

            18.1.16.5. Strategy Overview

                18.1.16.5.1. Marketing Strategy

        18.1.17. Marina Biotech

            18.1.17.1. Overview

            18.1.17.2. Product Portfolio

            18.1.17.3. Profitability by Market Segments

            18.1.17.4. Sales Footprint

            18.1.17.5. Strategy Overview

                18.1.17.5.1. Marketing Strategy

        18.1.18. miRagen Therapeutics, Inc.

            18.1.18.1. Overview

            18.1.18.2. Product Portfolio

            18.1.18.3. Profitability by Market Segments

            18.1.18.4. Sales Footprint

            18.1.18.5. Strategy Overview

                18.1.18.5.1. Marketing Strategy

        18.1.19. Synlogic, Inc.

            18.1.19.1. Overview

            18.1.19.2. Product Portfolio

            18.1.19.3. Profitability by Market Segments

            18.1.19.4. Sales Footprint

            18.1.19.5. Strategy Overview

                18.1.19.5.1. Marketing Strategy

        18.1.20. OncoGenex Pharmaceuticals Inc.

            18.1.20.1. Overview

            18.1.20.2. Product Portfolio

            18.1.20.3. Profitability by Market Segments

            18.1.20.4. Sales Footprint

            18.1.20.5. Strategy Overview

                18.1.20.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

DNA/RNA Extraction Market

Published : June 2023

Healthcare

RNA-Targeted Small Molecules Market

Published : September 2021

Explore Healthcare Insights

View Reports

Antisense Oligonucleotides Market